$BLGO Cashflow Statement | Understand Stock

$BLGO

$0.09 -$0.00 (2.78%) Close

$BLGO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense
Common stock issued for services
Impairment expense
Inventory reserve
Common stock issued for interest
Credit loss expense
Operating lease right-of-use assets amortization
Finance lease right -of-use asset amortization
Operating lease liabilities, net
Finance lease liability, net
Interest expense related to amortization of the discount on note payable
Loss on extinguishment of debt
Fair value of warrants issued for a fee and interest
Loss on investment in South Korean joint venture
PPP forgiveness
Depreciation expense
Bad debt expense

Changes in assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other assets
Lease liability, net
Accounts payable and accrued expenses
Entities, Excluding Partially Owned Subsidiary
Partially Owned Subsidiary
Deposits
Contract liabilities
Net cash used in operating activities
Cash flows from investing activities
Equipment purchases
Patent purchase
Investment in South Korean joint venture
Clyra Medical note receivable
Partially Owned Subsidiary
Total clyra Medical note receivable
Repayment of note receivable
Net cash provided by (used in) investing activities

Cash flows from financing activities
Proceeds from sale of common stock, net of offering costs
Partially Owned Subsidiary
Clyra Medical Common Stock
BETI Common Stock
Total proceeds from sale of common stock, net of offering costs
Proceeds from SBA loans
Proceeds from BioLargo stock option exercise
Partially Owned Subsidiary
Clyra Medical Common Stock
Total proceeds from BioLargo stock option exercise
Repayment of note payable and line of credit
Proceeds received by Clyra from inventory line of credit
Repayment by Clyra on inventory line of credit
Proceeds from debt obligation, net
Proceeds from BioLargo warrant exercise
Partially Owned Subsidiary
BioLargo Energy Technologies, Inc (BETI)
Clyra Medical Technologies
Total proceeds from BioLargo warrant exercise
Proceeds (repayments) from debt obligations, net
Repayment by Clyra Medical on inventory line of credit
Partially Owned Subsidiary
Total repayment by Clyra Medical on inventory line of credit
Proceeds from sale of preferred stock in Clyra Medical
Partially Owned Subsidiary
Total proceeds from sale of preferred stock in Clyra Medical
Proceeds from Clyra Medical note payable
Partially Owned Subsidiary
Total proceeds from Clyra Medical note payable
Net cash provided by financing activities
Net change in cash
Cash at beginning of year
Cash at end of year

Net effect of foreign currency translation
Supplemental disclosures of cash flow information
Interest
Income taxes
Short-term lease payments not included in lease liability
Non-cash investing and financing activities
Return of in-process research and development (Scion)
Cancellation of Clyra debt obligations and accounts payable (Scion)
Liability to Scion shareholders
Conversion of accounts receivable to a note receivable
Clyra preferred series A dividend
Series A Preferred Stock
Total clyra preferred series A dividend
Conversion of debt into shares of BioLargo common stock
Conversion of Debt into Shares of Common Stock
Total conversion of debt into shares of BioLargo common stock
Conversion of BETI common sotck to BioLargo common stock
Fair value of warrants issued with Clyra Medical note payable
BioLargo debt obligations exchanged for BETI noncontrolling interest
Fair value of common stock issued to Lincoln Park as finance fee
Conversion of convertible notes payable into common stock
Present value of new operating right of use and lease liability
Deemed dividend
Deferred offering costs recorded as additional paid in capital
Shares Issued
Fair value of Clyra shares issued as commitment fee
Present value of new Clyra Medical right-of-use asset and operating lease liability
Present value of new financing right of use and lease liability
Allocation of noncontrolling interest
Conversion of Intercompany Receivable into Clyra Shares
Total allocation of noncontrolling interest

Comments